KalVista Pharmaceuticals Inc (KALV)

Healthcare | Biotechnology
Income Statement (Quarterly) 2025-07-31 2025-01-31 2024-10-31 2024-07-31
Revenue 1,426,000 0 0 0
Cost of Revenue 590,000 0 0 224,000
Gross Profit 836,000 0 0 -224,000
Operating Expenses
R&D Expenses 0 0 0 0
SG&A Expenses 44,683,000 30,346,000 29,201,000 17,601,000
Operating Expenses 59,845,000 42,940,000 45,811,000 44,215,000
Operating Income -59,009,000 -42,940,000 -45,811,000 -44,215,000
Interest Expense 3,522,000 2,842,000 0 0
Income Before Tax -57,939,000 -44,262,000 -42,268,000 -40,443,000
Income Tax Expense 2,157,000 4,247,000 0 0
Net Income -60,096,000 -48,509,000 -42,268,000 -40,443,000
Per Share
EPS -1.12 -0.92 -0.91 -0.87
EPS Diluted 0.00 0.00 0.00 0.00
Income Statement (Annual) 2025-04-30 2024-04-30 2023-04-30 2022-04-30 2021-04-30
Revenue 0 0 0 0 0
Cost of Revenue 941,000 86,167,000 802,000 743,000 0
Gross Profit -941,000 -86,167,000 -802,000 -743,000 0
Operating Expenses
R&D Expenses 0 0 0 0 0
SG&A Expenses 116,286,000 54,278,000 30,595,000 26,446,000 16,637,000
Operating Expenses 187,995,000 54,278,000 110,871,000 96,613,000 57,923,000
Operating Income -187,995,000 -140,445,000 -110,871,000 -96,613,000 -57,923,000
Interest Expense 5,785,000 0 0 1,090,000 0
Income Before Tax -180,052,000 -135,096,000 -92,907,000 -82,339,000 -46,244,000
Income Tax Expense 3,392,000 -8,452,000 -18,054,000 -13,827,000 0
Net Income -183,444,000 -126,644,000 -74,853,000 -68,512,000 -46,244,000
Per Share
EPS -3.69 -3.44 -2.68 -2.80 -2.42
EPS Diluted 0.00 0.00 0.00 0.00 0.00
Balance Sheet (Quarterly) 2025-04-30 2024-04-30 2023-04-30 2022-04-30
Assets
Cash and Cash Equivalents 98,644,000 31,789,000 56,238,000 30,732,000
Short Term Investments 89,002,000 178,612,000 93,137,000 135,470,000
Net Receivables 15,141,000 10,871,000 16,568,000 14,098,000
Inventory 0 0 0 2,709,000
Total Current Assets 241,690,000 225,690,000 172,326,000 193,647,000
Property Plant Equipment 1,988,000 9,147,000 10,770,000 10,040,000
Goodwill and Intangibles 0 0 0 0
Total Assets 250,770,000 235,404,000 183,202,000 203,880,000
Liabilities
Account Payables 4,883,000 9,107,000 4,817,000 3,638,000
Short Term Debt 3,954,000 1,302,000 1,087,000 977,000
Total Current Liabilities 45,167,000 22,807,000 15,032,000 11,576,000
Long Term Debt 4,330,000 6,015,000 7,145,000 7,211,000
Total Liabilities 155,379,000 28,822,000 22,177,000 18,787,000
Shareholders Equity
Retained Earnings -653,170,000 -469,726,000 -343,082,000 -250,175,000
Total Shareholders Equity 95,391,000 206,582,000 161,025,000 185,093,000
Balance Sheet (Annual) 2025-04-30 2024-04-30 2023-04-30 2022-04-30 2021-04-30
Assets
Cash and Cash Equivalents 98,644,000 31,789,000 56,238,000 30,732,000 50,592,000
Short Term Investments 89,002,000 178,612,000 93,137,000 135,470,000 198,337,000
Net Receivables 15,141,000 10,871,000 16,568,000 14,098,000 10,418,000
Inventory 0 0 0 2,709,000 0
Total Current Assets 241,690,000 225,690,000 172,326,000 193,647,000 264,264,000
Property Plant Equipment 1,988,000 9,147,000 10,770,000 10,040,000 7,549,000
Goodwill and Intangibles 0 0 0 0 0
Total Assets 250,770,000 235,404,000 183,202,000 203,880,000 272,013,000
Liabilities
Account Payables 4,883,000 9,107,000 4,817,000 3,638,000 1,981,000
Short Term Debt 3,954,000 1,302,000 1,087,000 977,000 863,000
Total Current Liabilities 45,167,000 22,807,000 15,032,000 11,576,000 9,774,000
Long Term Debt 4,330,000 6,015,000 7,145,000 7,211,000 5,046,000
Total Liabilities 155,379,000 28,822,000 22,177,000 18,787,000 14,820,000
Shareholders Equity
Retained Earnings -653,170,000 -469,726,000 -343,082,000 -250,175,000 -167,836,000
Total Shareholders Equity 95,391,000 206,582,000 161,025,000 185,093,000 257,193,000
Cash Flow Statement (Quarterly) 2025-04-30 2024-04-30 2023-04-30 2022-04-30
Operating Activities
Net Income -183,444,000 -126,644,000 -92,907,000 -82,339,000
Depreciation & Amortization 955,000 816,000 718,000 564,000
Stock Based Compensation 0 21,915,000 9,922,000 11,086,000
Change in Working Capital 22,281,000 15,167,000 7,413,000 -12,322,000
Operating Cash Flow -152,907,000 -89,231,000 -75,261,000 -78,134,000
Investing Activities
Capital Expenditure -434,000 -443,000 -1,196,000 -931,000
Investments 0 0 -1,196,000 -931,000
Investing Cash Flow 91,024,000 -84,719,000 41,415,000 57,860,000
Financing Activities
Debt Repayment 98,040,000 0 0 0
Common Stock Issued/Repurchased 61,687,000 96,945,000 56,582,000 1,581,000
Dividends Paid 0 0 0 0
Financing Cash Flow 159,727,000 150,714,000 58,116,000 1,581,000
Summary
Free Cash Flow -152,907,000 -89,674,000 -76,457,000 -79,065,000
Net Change in Cash 100,483,000 -24,449,000 25,506,000 -19,860,000
Cash Flow Statement (Annual) 2025-04-30 2024-04-30 2023-04-30 2022-04-30 2021-04-30
Operating Activities
Net Income -183,444,000 -126,644,000 -92,907,000 -82,339,000 -46,244,000
Depreciation & Amortization 955,000 816,000 718,000 564,000 537,000
Stock Based Compensation 0 21,915,000 9,922,000 11,086,000 7,118,000
Change in Working Capital 22,281,000 15,167,000 7,413,000 -12,322,000 8,346,000
Operating Cash Flow -152,907,000 -89,231,000 -75,261,000 -78,134,000 -30,171,000
Investing Activities
Capital Expenditure -434,000 -443,000 -1,196,000 -931,000 -82,000
Investments 0 0 -1,196,000 -931,000 -82,000
Investing Cash Flow 91,024,000 -84,719,000 41,415,000 57,860,000 -147,654,000
Financing Activities
Debt Repayment 98,040,000 0 0 0 0
Common Stock Issued/Repurchased 61,687,000 96,945,000 56,582,000 1,581,000 210,582,000
Dividends Paid 0 0 0 0 0
Financing Cash Flow 159,727,000 150,714,000 58,116,000 1,581,000 212,117,000
Summary
Free Cash Flow -152,907,000 -89,674,000 -76,457,000 -79,065,000 -30,253,000
Net Change in Cash 100,483,000 -24,449,000 25,506,000 -19,860,000 34,803,000